Handing drug development work from one vendor to the next brings costs that rarely show up in the first quote. Each handoff means repeated work and lost weeks, and it can draw more questions from regulators. Keeping development and manufacturing with one partner avoids many of these costs.
That makes an integrated approach worth budgeting for in 2027. Two changes make this more urgent now. New US limits on certain biotech suppliers could start applying as early as 2027. At the same time, finance teams are pushing for project costs they can predict. Both are good reasons to count the full cost of handoffs before signing the next vendor contract.
Why Did Split-Vendor API Development Look Cheaper on Paper?
Split-vendor API development looked cheaper because each quote covered only one stage of the work. Companies compared these quotes side by side and picked the lowest price at each stage. On paper, that looked like smart cost control. What those quotes left out was the cost of moving the project from one vendor to the next.
Those moving costs are easy to miss because no single vendor includes them in its price. When a project shifts to a new vendor, both sides first need to sign fresh confidentiality and quality agreements. The new vendor then has to find space for the project in its production schedule. Until both steps are done, no work can start at the new site. The delay is real, but it does not show up in any stage quote.
The company’s own staff time is missing from the quotes too. Someone has to manage each move and brief every new team on the project. With three or four vendors, this becomes a steady part of someone’s workload.
An integrated partner brings these hidden costs into one plan. With end-to-end API development and manufacturing, one partner handles the project from early lab work through commercial supply. The project still moves between teams, but under the same agreements and the same schedule. So a single quote from that partner shows far more of the true project cost.
What Hidden Costs Do Handoffs Add to API Development?
Handoffs add hidden costs to API development in three ways. Two appear during the transfer itself, and one appears later, in the regulatory filing.
Transfer Work Gets Repeated at Every New Site
Every new partner must prove the process works in its own facility. It sets up the test methods again and runs fresh trial batches, repeating work the last site already did. In multi-vendor API development, the company pays for this material and reactor time at every move.
Process Knowledge Rarely Travels With the Paperwork
Transfer documents list the steps and settings for running the process. They rarely record the lessons the original chemists learned along the way. For example, a reaction may fail if the temperature drifts slightly. If that lesson is missing, the new team may learn it through a failed batch.
Data From Several Sites Can Weaken the Regulatory Filing
Regulators need proof that every batch meets the same quality standard. That proof is harder to give when batches come from different sites, each with its own equipment and methods. When the results don’t line up, regulators ask for more data, often late in the review.
A study of FDA complete response letters shows what these late questions can cost. The FDA sends such a letter when it cannot yet approve a drug. Across 43 new drugs, 65% of these letters cited facility issues and 51% cited CMC issues. The typical wait from letter to approval was about 15 months.
Why Does Integrated API Development Belong in 2027 Budgets?
Integrated API development belongs in 2027 budgets because handoffs are becoming harder to avoid and riskier to get wrong. New US supplier rules may push some companies to change partners. Meanwhile, the reasons behind approval delays are now easier for outsiders to see.
The supplier rules come from the BIOSECURE Act, which became law in December 2025. It restricts US federal contracts and grants that involve certain foreign biotech suppliers. The government must name more of these suppliers by December 2026. The main restrictions are not expected to apply before 2027. Companies that rely on a listed vendor may therefore need to move their work from 2027 onward.
That move creates a new handoff. The new partner must repeat testing and trial batches before production resumes. If the change could affect product quality, the FDA may also need to approve it first. So, budgeting for this now helps companies avoid a rushed switch later. It also lets them pick one partner for all remaining stages, which avoids further handoffs.
A rushed switch carries a second risk, because approval delays are now public. In 2025, the FDA began publishing its complete response letters, which explain why a drug is not yet approved. Investors and partners can now see any manufacturing problems behind a delay. Consistent data from a single partner lowers that risk, so it is worth funding from the start.
What Should Companies Look for in an Integrated API Development Partner?
Companies should look for a partner that carries one molecule from early chemistry to commercial supply in-house. Many vendors list every service. The real test is whether those services run as one connected process. Here are four areas worth checking in any integrated API development partner:
One Data Trail From Route Scouting to Commercial Supply
Start with how the partner keeps records. Development and manufacturing teams should share one documentation system. Lab and plant batches can then be compared without piecing data together. Ask to see how this worked on a past project.
Test Methods That Hold Up as Batch Size Grows
Testing works the same way. Methods built early should carry through to commercial batches with only minor changes. If they are rebuilt at each scale, the handoff cost has simply moved in-house.
Regulatory Approvals That Match Target Markets
Approvals come next, because they decide where your molecule can be sold. The commercial site should hold approvals from regulators in each market you plan to enter. Check its recent inspection results too. Confirming this early avoids a move to another site later.
Enough Capacity to Scale Without Moving Sites
Running out of room can also force a late site move. Ask whether that same site has reactor capacity for your expected commercial volumes. Also ask how far ahead production slots are booked. A site move late in development brings back the transfer work covered earlier.
Neuland Laboratories is one partner built along these lines. The company develops and manufactures small molecule and peptide APIs, from route scouting through commercial supply. Its 400+ R&D scientists work alongside kilo lab and pilot plant teams. That keeps each step up in scale connected to earlier work. More than 1.2 million liters of API reactor capacity gives projects room to grow. Neuland’s three cGMP-certified facilities also hold FDA and EMA approvals, along with Japan’s PMDA. So, companies planning 2027 budgets around fewer handoffs can get in touch with Neuland today.
FAQs
-
Is an integrated API partner always cheaper than using several vendors?
An integrated API partner is not always cheaper at each stage. Its price for a single stage can even be higher than a specialist’s. The savings tend to show up across the full project. So the fairest comparison is the total cost from early development to commercial supply.
-
When is the best time to choose an integrated API partner?
The best time to choose an integrated API partner is before making the first batches for clinical trials. Switching gets harder once a site’s data supports a regulatory filing. Good moments to decide include:
- Before scaling up from lab work to the kilo lab
- When a current vendor cannot support the next stage
-
Does the BIOSECURE Act affect companies without US government contracts?
The BIOSECURE Act does not directly restrict companies without US federal contracts or grants. It can still affect them indirectly. Partners or investors with federal funding may prefer suppliers that are not on the list. Legal teams should review how each supplier relationship could be affected.
-
Can a company keep a second supplier while working with an integrated partner?
Yes, a company can keep a second supplier alongside an integrated partner. Some companies do this for commercial supply, so one site problem does not halt production. Timing is what matters most here. Adding a backup site after the process is stable is simpler than splitting early development across vendors.
